IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
0.326
-0.006 (-1.81%)
At close: Mar 5, 2026, 4:00 PM EST
0.336
+0.010 (3.16%)
After-hours: Mar 5, 2026, 7:12 PM EST
IO Biotech Stock Forecast
IOBT's stock price has decreased by -64.37% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for IO Biotech stock have an average target of 2.25, with a low estimate of 0.50 and a high estimate of 4.00. The average target predicts an increase of 590.61% from the current stock price of 0.33.
Analyst Consensus: Hold
* Price targets were last updated on Jan 26, 2026.
Analyst Ratings
The average analyst rating for IO Biotech stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 2 | 2 | 2 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $3 → $0.5 | Buy → Hold | Downgrades | $3 → $0.5 | +53.47% | Jan 26, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $3 | Buy | Maintains | $10 → $3 | +820.81% | Oct 22, 2025 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 29, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +1,127.75% | Aug 12, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
4.60M
EPS This Year
-1.27
from -1.45
EPS Next Year
-0.37
from -1.27
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 14.2M | ||||
| Avg | n/a | 4.6M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.25 | -0.06 | |||
| Avg | -1.27 | -0.37 | |||
| Low | -1.27 | -0.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.